Clinical Trials Logo
  1. Home
  2. Ovarian Cancer
  3. NCT01689714
  4. Details
NCT01689714 Clinical Trial

Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma

Ovarian Carcinoma Clinical Trial

Official title:
A MULTI-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FOLATESCAN (TECHNETIUM Tc 99m EC20) IN PATIENTS WITH SUSPECTED OVARIAN CARCINOMA OR RECURRENT ENDOMETRIAL CARCINOMA

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01689714
Other study ID # EC20.4
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 2003
Est. completion date August 2005

Study information
Verified date September 2012
Source Endocyte
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The folate receptor is overexpressed in many types of cancer, including ovarian and endometrial cancer, and the level of folate receptor expression increases with the stage of the disease. Technetium Tc 99m EC20 (99mTc-EC20; FolateScan), a folate-targeted diagnostic radiopharmaceutical, is designed to bind to the folate receptor. Thus, FolateScan may provide an effective method to determine folate receptor-positive (FR+) target tumors, thereby assisting in the identification of those patients who may benefit from folate-targeted therapy.

Description:

This phase 2, two-center, open-label, single-treatment group, within-patient-controlled study was conducted to: - Expand the safety database and gather data on the percentage of patients with known or suspected ovarian carcinoma or recurrent endometrial carcinoma who show increased uptake of FolateScan in tumors (primary objective). - Calculate the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of FolateScan compared with immunohistochemical (IHC) staining (secondary objective).

Recruitment information / eligibility
Status Completed
Enrollment 16
Est. completion date August 2005
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects must meet the following eligibility requirements to be enrolled in the study. 1. Subject must be 18 years of age or older. 2. Subject must have known or strongly suspected ovarian carcinoma or recurrent endometrial carcinoma with at least one identifiable lesion > 1.5 cm as diagnosed by ultrasonography, MRI, or CT. 3. Subject must have good kidney function. 4. Subject must provide written informed consent prior to enrollment. Exclusion Criteria: - Subjects must be excluded if any of the following conditions are present: 1. Subject is pregnant or breastfeeding. 2. Subject is simultaneously participating in another investigational drug study. 3. Subject has completed the follow-up phase of any previous study less than 30 days prior to enrollment in this study. 4. Subject is unable to tolerate conditions for radionuclide imaging. 5. Subject has been administered another radiopharmaceutical that would interfere with the assessment of Technetium Tc 99m EC20.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Tc 99m EC20

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Endocyte
See also
  Status Clinical Trial Phase
Recruiting NCT05494580 - Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Phase 1/Phase 2
Withdrawn NCT02530606 - Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer N/A
Active, not recruiting NCT02244502 - Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE) Phase 1/Phase 2
Terminated NCT02218502 - Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses N/A
Terminated NCT01936974 - (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma Phase 2
Recruiting NCT02073500 - Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Completed NCT00756847 - Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors Phase 1
Withdrawn NCT02878980 - An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients N/A
Active, not recruiting NCT02194387 - Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members N/A
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT04251052 - A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer N/A
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Completed NCT00989651 - Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Not yet recruiting NCT05591560 - Itraconazole in Advanced Ovarian Cancer N/A
Completed NCT01481701 - A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma Phase 2
Completed NCT00181701 - Intraperitoneal Paclitaxel and Carboplatin in the Treatment of Women With Carcinoma of Mullerian Origin Phase 2
Terminated NCT00047632 - Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer Phase 3
Recruiting NCT03302884 - Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma N/A
Completed NCT02166905 - DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission Phase 1/Phase 2
Recruiting NCT04851119 - Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Phase 1/Phase 2